Fleur Hudson

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Stephen R. Russell, Jean Bennett, Jennifer Wellman et al. · The Lancet · 2017 · 1.8K citations · Full text

Ocular Disease, Retina, Ophthalmology +6

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

John Collinge, Michele Gorham, Fleur Hudson et al. · The Lancet Neurology · 2009 · 259 citations · Full text

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, Abdel G. Babiker, Laura Richert et al. · The Lancet · 2014 · 172 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +10

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

Sarah Fidler, Wolfgang Stöhr, Lucy Dorrell et al. · The Lancet · 2020 · 135 citations

Antiretroviral Therapy, Hiv/aids Counselling, Treatment And Prevention +8

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Thomas L Holland, Adit A. Ginde, Roger Paredes et al. · The Lancet Respiratory Medicine · 2022 · 124 citations · Full text

Covid-19 Pandemic, Antiviral Therapy, Clinical Trials +3